NICE deem prostate cancer drug too expensive
A prostate cancer drug is too expensive for use on the NHS, a watchdog has ruled.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
Customised email alerts straight to your inbox (over 30 alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units